Tuesday, April 17, 2007

ApopLogic Pharmaceuticals Wins the Second Annual Faegre & Benson Venture Showcase Award, Presented at BioWest 2006


Denver, CO, August 25, 2006 -- ApopLogic Pharmaceuticals (Aurora) won the second annual Faegre & Benson Venture Showcase Award at BioWest 2006. The announcement is made by Chris Shapard, bioscience director at the Colorado Office of Economic Development and International Trade (OEDIT), who says the $10,000 Venture Showcase Award was again provided by the Faegre & Benson law firm and announced at the Colorado Bioscience Association (CBSA) Awards banquet held Thursday evening at the Colorado Convention Center.

ApopLogic Pharmaceuticals is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target apoptotic cell death pathways found in tumor cells and proliferating immune cells (lymphocytes). The Company was formed in 2006 to capitalize on the intellectual property of its Founding Scientists and University of Colorado Cancer Center members, Richard C. Duke, Ph.D., Donald Bellgrau, Ph.D., Paul A. Bunn, M.D., Daniel Chan, Ph.D., Lajos Gera, Ph.D., Jaime Modiano, D.V.M., Ph.D. and John Stewart, Ph.D. Putting it most simply, ApopLogic induces cancer cells and autoimmune lymphocytes to commit suicide. Therapeutic products include:


  • Breceptin: A novel neuropeptide growth factor receptor antagonist that targets a broad range of cancers.

  • Cytonil: A proprietary combination of a cell-type specific growth factor and a cell signaling agonist to treat Sezary leukemia, cutaneous T cell lymphoma and psoriasis.

  • Fasaret: A proprietary therapy based on Fas ligand, an apoptotic cell death-inducing molecule with unique pro-inflammatory properties, for the treatment of cancers.
Building on strong pre-clinical data, ApopLogic Pharmaceuticals is outlining detailed clinical development plans to rapidly move Breceptin and Fasaret into phase 1 human clinical trials that could begin within 12 months of series A financing.

ApopLogic Pharmaceuticals, LLC is a startup phase biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products that target apoptotic cell death pathways found in cancers, leukemias and lymphomas. The Company was formed in 2006 to capitalize on the intellectual property of its Founding Scientists and University of Colorado Cancer Center members, Richard C. Duke, Ph.D., Donald Bellgrau, Ph.D., Paul A. Bunn, M.D., Daniel Chan, Ph.D., Lajos Gera, Ph.D., Jaime Modiano, D.V.M., Ph.D. and John Stewart, Ph.D. Put most simply, ApopLogic is inducing rapidly dividing cells to commit suicide. Visit: http://www.apoplogic.com/.

No comments:

Post a Comment